drugset / Trial / NCT00605267

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

NCT00605267

Phase 3 Completed 197 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this multi-centre, randomised, double-blind, parallel-group study is to compare efficacy and safety between anastrozole and tamoxifen in pre- and post-operative administration under goserelin acetate treatment for premenopausal breast cancer patients

Timeline

Start
2007-10
Primary completion
2009-11
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Comparator Tamoxifen Small molecule 20 mg Oral
Background Goserelin Other / unclassified 3.6 mg Other

Indications